Patients must have a diagnosis of metastatic hormone-sensitive prostate cancer
Patients must be ≥19 years of age
Patients must have stable PSA \<4.0 ng/mL at the time of enrollment (PSA stability includes decreasing PSA, non-increasing PSA, or PSA not increasing by an absolute level of ≥0.2ng/mL on 2 consecutive checks)
Patients must be receiving therapy with continuous ADT with GnRH agonist (Leuprolide, Goserelin, or Triptorelin) plus ARPI (Abiraterone acetate with prednisone, Enzalutamide, Apalutamide, or Darolutamide) for ≥18 months
ECOG ≤2
Testosterone \<50ng/dL
You may not be if
ECOG\>2
Surgical castration
Second malignancy likely to affect life expectancy
Greater than 1 appointment no show in the last year
